Skip to main content
main-content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Concomitant TKI–PPI use may adversely affect cancer patient survival

Pills_various

Taking proton pump inhibitors alongside tyrosine kinase inhibitors is associated with an increased mortality risk in older cancer patients, research indicates.

No difference in efficacy of cancer immunotherapy by sex

Male & female symbols_chalk

Both men and women derive an overall survival advantage from treatment with immunotherapeutic agents for advanced solid tumors, a meta-analysis shows.

Direct oral anticoagulants AVERT VTE events in patients with cancer

Blood clot

The results of the randomized CASSINI and AVERT trials support the prophylactic use of the direct oral anticoagulants rivaroxaban and apixaban in cancer patients undergoing chemotherapy who are at risk for venous thromboembolism events.

Experts reflect on their highlights from ESMO 2018

ESMO flags

Hisham Mehanna, Ricardo Alvarez and Massimo Christofanilli, and Thomas Seufferlein discuss their ESMO 2018 highlights in head & neck, breast, and gastrointestinal cancer, respectively (7:42).

Latest headlines

18-01-2019 | Renal cell carcinoma | News

Potential ‘risk of harm’ for older women with adjuvant sunitinib for RCC

Adjuvant treatment with sunitinib may be associated with an increased mortality risk for older female patients with renal cell carcinoma, suggests a post-hoc analysis of the ASSURE trial that compared sunitinib and sorafenib with placebo.

18-01-2019 | Non-small cell lung cancer | News

Prolonged OS possible for ALK-positive stage IV NSCLC

Individuals with stage IV non-small-cell lung cancer harboring anaplastic lymphoma kinase translocations can hope to achieve overall survival of nearly 7 years, suggests a US cohort analysis.

16-01-2019 | Castration-resistant prostate cancer | News

Germline BRCA2 mutations impact mCRPC survival

Germline mutations in the BRCA2 gene, but not other DNA damage repair genes, are associated with poorer outcomes among patients with metastatic castration-resistant prostate cancer, study findings indicate.

In depth

12-12-2018 | Immunotherapy | Feature | Article

Hyperprogression as a response to immunotherapy: ‘A serious downside’

In light of recent reports of hyperprogression in response to treatment with cancer immunotherapy, medwireNews spoke to medical oncologist Razelle Kurzrock (University of California, San Diego, La Jolla, USA) about the phenomenon, the implications for therapy, and future directions for research.

Researcher comment: COMPARE study

Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to make accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research

ALL and infection: Unpicking the connection

Professor Mel Greaves (Institute of Cancer Research, London, UK) discusses his proposed theory for the etiology of childhood acute lymphoblastic leukemia, in which early microbial exposure plays a key role.

image credits